Angiotensin II receptor antagonists
View Patent ↗A compound having the structure wherein R is an angiotensin receptor antagonist active group, Y is -Y 1 -Y 2 -Y 3 -Y 4 -Y 5 -; Y 1 is C(R 1 R 2 ); R 1 is selected from the group consisting of hydrogen and C 1-4 alkyl; R 2 is selected from the group consisting of hydrogen, C 1-4 alkyl, and —OC(O)C 1-4 alkyl; Y 2 is O or CH 2 ; Y 3 is C(O) or CH 2 ; Y 4 is O or CH 2 ; Y 5 is —(CH 2 ) 1-2 —(X) 0-1 —(CH 2 ) 0-1 — or is absent; X is —O— or —CR 3 R 4 —; and R 3 and R 4 are independently selected from the group consisting of hydrogen and C 1 -C 4 alkyl; or a pharmaceutically acceptable salt or hydrate thereof, which is useful for treating hypertension.
1. A compound having the following formula:
or a pharmaceutically acceptable salt of the compound.
2. A compound of claim 1 , or a pharmaceutically acceptable salt thereof, selected from the group consisting of
1-[({[(5R)-5,6-bis(nitrooxy)hexyl]oxy}carbonyl)oxy]ethyl 2-butyl-4-chloro-1-{[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylate—Diastereomer A, and
1-[({[(5R)-5,6-bis(nitrooxy)hexyl]oxy}carbonyl)oxy]ethyl 2-butyl-4-chloro-1-{[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylate—Diastereomer B.
3. A compound of claim 2 , or a pharmaceutically acceptable salt thereof, which is
1-[({[(5R)-5,6-bis(nitrooxy)hexyl]oxy}carbonyl)oxy]ethyl 2-butyl-4-chloro-1-{[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylate—Diastereomer A.
4. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
5. A pharmaceutical composition comprising a compound of claim 1 , a diuretic, and a pharmaceutically acceptable carrier.
6. A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier.
7. A pharmaceutical composition comprising a compound of claim 3 , a diuretic, and a pharmaceutically acceptable carrier.